Seagen Signs Collaboration and License Agreement with Zai Lab for Tivdak®
By Ayush Saxena
Pharma Deals Review: Vol 2022 Issue 10 (Table of Contents)
Published: 6 Oct-2022
DOI: 10.3833/pdr.v2022.i10.2729 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Seagen has entered into a collaboration and licensing agreement with Zai Lab for the development and commercialisation of Tivdak®(tisotumab vedotin-tftv) in mainland China, Hong Kong, Macau, and Taiwan...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS